M
Michelle Ferrari
Researcher at Stanford University
Publications - 37
Citations - 3005
Michelle Ferrari is an academic researcher from Stanford University. The author has contributed to research in topics: Prostate cancer & Prostatectomy. The author has an hindex of 19, co-authored 37 publications receiving 2839 citations.
Papers
More filters
Journal ArticleDOI
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
Jacques Lapointe,Chunde Li,John P. Higgins,Matt van de Rijn,Eric Bair,Kelli Montgomery,Michelle Ferrari,Lars Egevad,Walter Rayford,Ulf S.R. Bergerheim,Peter Ekman,Angelo M. DeMarzo,Robert Tibshirani,David Botstein,Patrick O. Brown,James D. Brooks,Jonathan R. Pollack +16 more
TL;DR: It is suggested that prostate tumors can be usefully classified according to their gene expression patterns, and these tumor subtypes may provide a basis for improved prognostication and treatment stratification.
Journal ArticleDOI
Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis
Jacques Lapointe,Chunde Li,Craig P. Giacomini,Keyan Salari,Stephanie Huang,Pei Wang,Michelle Ferrari,Tina Hernandez-Boussard,James D. Brooks,Jonathan R. Pollack +9 more
TL;DR: The findings reveal that prostate cancers develop via a limited number of alternative preferred genetic pathways and provide a new framework for investigating prostate cancer biology and explain in part the clinical heterogeneity of the disease.
Journal ArticleDOI
Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radiation Treated Patients
TL;DR: Serum prostate specific antigen was determined (Yang polyclonal radioimmunoassay) in 183 men after radiation therapy for adenocarcinoma of the prostate and total serum acid phosphatase levels were poorly related to prostate Specific Antigen levels, were less effective in discriminating patients with metastatic disease and provided no additional information beyond that provided by prostatespecific antigen.
Journal ArticleDOI
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
TL;DR: Data suggest that serum prostate specific antigen determination 6 months after introduction of therapy is capable of distinguishing patients with a favorable and persisting response to anti-androgen therapy from those in whom a limited response can be expected.
Journal ArticleDOI
The male bulbourethral sling procedure for post-radical prostatectomy incontinence
TL;DR: The male bulbourethral sling procedure is effective treatment for post-radical prostatectomy urinary incontinence and patients who had received adjuvant radiation therapy demonstrated a lower continence rate than those who had not.